Literature DB >> 29025740

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Chatree Chai-Adisaksopha1,2, Jennifer R Brown3.   

Abstract

In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.
© 2017 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29025740     DOI： 10.1182/blood-2017-07-731588

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  14 in total

1.  Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Authors:  Sanford Kempin; Zhuoxin Sun; Neil E Kay; Elisabeth M Paietta; Joseph J Mazza; Rhett P Ketterling; Olga Frankfurt; David F Claxton; Joel N Saltzman; Gordan Srkalovic; Natalie S Callander; Gerald Gross; Martin S Tallman
Journal:  Acta Haematol       Date:  2019-07-23       Impact factor: 2.195

2.  Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.

Authors:  Tomasz K Wojdacz; Harindra E Amarasinghe; Latha Kadalayil; Alice Beattie; Jade Forster; Stuart J Blakemore; Helen Parker; Dean Bryant; Marta Larrayoz; Ruth Clifford; Pauline Robbe; Zadie A Davis; Monica Else; Dena R Howard; Basile Stamatopoulos; Andrew J Steele; Richard Rosenquist; Andrew Collins; Andrew R Pettitt; Peter Hillmen; Christoph Plass; Anna Schuh; Daniel Catovsky; David G Oscier; Matthew J J Rose-Zerilli; Christopher C Oakes; Jonathan C Strefford
Journal:  Blood Adv       Date:  2019-08-27

Review 3.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

4.  A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Han Gong; Heng Li; Qin Yang; Guangxiong Zhang; Hong Liu; Zekang Ma; Hongling Peng; Ling Nie; Xiaojuan Xiao; Jing Liu
Journal:  Biomed Res Int       Date:  2022-07-06       Impact factor: 3.246

5.  Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Authors:  Francesc Bosch; Guy Cantin; Agostino Cortelezzi; Wolfgang Knauf; Mourad Tiab; Mehmet Turgut; Andrey Zaritskey; Jean-Louis Merot; Eugen Tausch; Kerstin Trunzer; Susan Robson; Ekaterina Gresko; Sebastian Böttcher; Robin Foà; Stephan Stilgenbauer; Véronique Leblond
Journal:  Leukemia       Date:  2019-08-27       Impact factor: 11.528

6.  Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

Authors:  Martin Gauthier; Françoise Durrieu; Elodie Martin; Michael Peres; François Vergez; Thomas Filleron; Lucie Obéric; Fontanet Bijou; Anne Quillet Mary; Loic Ysebaert
Journal:  BMC Cancer       Date:  2019-08-14       Impact factor: 4.430

Review 7.  Frontline therapies for untreated chronic lymphoid leukemia.

Authors:  Delong Liu; Juanjuan Zhao
Journal:  Exp Hematol Oncol       Date:  2019-08-17

Review 8.  Celebrating 20 Years of IGHV Mutation Analysis in CLL.

Authors:  Nicholas Chiorazzi; Freda K Stevenson
Journal:  Hemasphere       Date:  2020-01-22

9.  Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Jacques-Olivier Pers; Yves Renaudineau; Audrey Mohr; Adrian Tempescul; Boutahar Bendaoud; Stéphanie Deshayes; Florence Dalbies; Caroline Buors; Hussam Saad; Christian Berthou
Journal:  Oncotarget       Date:  2018-08-03

Review 10.  B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.

Authors:  Katerina Gemenetzi; Andreas Agathangelidis; Laura Zaragoza-Infante; Electra Sofou; Maria Papaioannou; Anastasia Chatzidimitriou; Kostas Stamatopoulos
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.